Russia wants to distribute its questionable coronavirus vaccine to other countries: report
- Russian President Vladimir
Putinwants to distribute its questionable Sputnik V coronavirus vaccineto other countries, Reuters reported Saturday. Russiafirst approved Sputnik V in August, but experts and healthofficials were skeptical the vaccine would work since it did not go through necessary phase 3 trials.
- The Kremlin also kept important information relevant to the vaccine's success out of the public's eye. This included its methodology.
Russian President Vladimir Putin said Saturday that the country is hoping to distribute its controversial Sputnik V
Russia announced a successful coronavirus vaccine in August, but Sputnik V was approved under questionable circumstances. It was released before it went through phase 3 trials. In the United States, phase 3 is a requirement before a drug or vaccine can be vetted and approved by the Food and Drug Administration.As Business Insider's Susie Neilson previously reported, the vaccine's early-trial results had not undergone peer review. Russia had also not revealed its methodology, further enshrouding Sputnik V in secrecy.
Speaking at the annual
Russia in August said it would start the mass production process in September, despite the uncertainty that plagued Sputnik V.Earlier this month, the Kremlin announced that preliminary data showed the vaccine had a 92% effectiveness rate at preventing the coronavirus. But the data was based on just 20 confirmed COVID-19 cases, according to a press release. Putin told news reporters in August that he had offered to help the United States develop a coronavirus vaccine, but the White House declined.
There are two coronavirus vaccines that have proven to have a high success rate at fighting the coronavirus. Pharmaceutical company Pfizer and biotech group Moderna announced earlier this month that they've developed vaccines with at least a 94.5% success rate at preventing the coronavirus in clinical trials.
- Rajasthan imposes night curfew in 13 districts till December 31, slashes COVID-19 test prices for private labs
- PM's visit to vaccine centres gets 'praise' from Congress
- Pollution, pandemic and pre-term birth
- Serum Institute of India threatens to seek ₹100 crore in damages from Chennai volunteer
- PM to interact with more teams of Covid-19 vaccine developers